Skip to main content

Table 3 Adverse events

From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

AEs, n (%) G1 G2 G3 G4 G3 + 4 All
Leukopenia 2 (6.3) 13 (40.6) 10 (31.3) 3 (9.4) 13 (40.6) 28 (87.5)
Neutropenia 1 (3.1) 5 (15.6) 8 (25) 14 (43.8) 22 (68.8) 28 (87.5)
Thrombocytopenia 14 (43.8) 2 (6.3) 1 (3.1) 0 1 (3.1) 17 (53.1)
Anemia 15 (46.9) 10 (31.3) 0 0 0 25 (78.1)
Febrile Neutropenia 0 0 3 (9.4) 0 3 (9.4) 3 (9.4)
Peripheral Neuropathy 0 9 (28.1) 4 (12.5) 0 4 (12.5) 13 (40.6)
Constipation 0 3 (9.4) 0 0 0 3 (9.4)
Dysgeusia 0 5 (15.6) 0 0 0 5 (15.6)
Fatigue 0 2 (6.3) 1 (3.1) 0 1 (3.1) 3 (9.4)
Fever 0 5 (15.6) 1 (3.1) 0 1 (3.1) 6 (18.8)
Oral Mucositis 0 4 (12.5) 1 (3.1) 0 1 (3.1) 5 (15.6)
Diarrhea 0 3 (9.4) 0 0 0 3 (9.4)
  1. The most commonly seen grade 3/4 haematological adverse events were neutropenia in 22 (68.8%) and leukopenia in 13 (40.6%) patients. The grade 3/4 non-haematological toxicities included peripheral neuropathy in four (12.5%) patients and febrile neutropenia in three (9.4%) patients
\